Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

This study has been completed.
Sponsor:
Collaborators:
Ministry of Health, France
Amgen
Baxter Healthcare Corporation
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00231582
First received: October 3, 2005
Last updated: February 24, 2011
Last verified: March 2007